What the proposal says
- The HHS chapter recommends reversing FDA's approval of mifepristone, or at minimum restoring in-person dispensing and earlier gestational limits and stopping mail-order distribution.[1]
Chapter 14: Department of Health and Human Services
Printed pages 458–459 · open PDF at page 490 (est.)
What has happened
What is in effect now
- Mifepristone can still be prescribed by telehealth and dispensed by mail or retail pharmacy.[2]
What remains incomplete
- AnalysisFDA has not changed the drug's approval or dispensing requirements as of the verification date.
Why it matters
- AnalysisMedication abortion is the most common method in the U.S.; restoring in-person dispensing would end telehealth access nationwide.
Uncertainty and disputed points
- AttributedReporting indicates FDA told a court its safety review should finish by March 2027; this date has not been confirmed from the court filing.[2]
Status history
| Date | Status | Note |
|---|---|---|
| May 14, 2026 | Not implemented | FDA review ongoing; Supreme Court preserves current rules. |
Sources
- [1]Mandate for Leadership: The Conservative Promise (Project 2025), full text The Heritage Foundation, 2023. Accessed Nov. 17, 2026. Archived copyPrinted page numbers are cited throughout. The project2025.org domain now redirects; this Heritage-hosted copy and the Internet Archive copy are retained.
- [2]Louisiana v. FDA: Access to Mifepristone Back at the Supreme Court KFF, May 14, 2026. Accessed Nov. 17, 2026.